CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the...
Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~75% of covered...
CELEBRATION, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the...
CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or...
The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety...
CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or...
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful...
U.S. index futures are nearly unchanged in pre-market trading this Thursday. The indexes are on track to close...
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.